Related Experiment Video
Updated: Jan 28, 2026
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
Published on: July 7, 2023
XPO6 mRNA as a Potential Biomarker for Major Depressive Disorder: Associations with Disease State and Treatment
Tien-Wei Hsu1,2,3,4, Tiao-Lai Huang5,6
1Department of Psychiatry, E-DA Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
Introduction:
Exportin-6 (XPO6) regulates nuclear export of actin and related proteins, processes essential for cytoskeletal integrity and synaptic function. Given the importance of these mechanisms in mood regulation, XPO6 dysregulation may contribute to the pathophysiology of major depressive disorder (MDD), yet its role remains largely unknown.
Method:
XPO6 mRNA was measured in the peripheral blood of participants with MDD in an acute depressive episode (acute MDD group), MDD in remission, and healthy controls (screened using Chinese health questionnaire-12 and semi-structured interviews to exclude current or past psychiatric disorders) at baseline. XPO6 mRNA levels were measured after 4 weeks of antidepressant treatment in the acute MDD group. The 17-item Hamilton Depression Rating Scale was used to assess depression severity. XPO6 mRNA levels were quantified by quantitative reverse transcription polymerase chain reaction (RT-qPCR).
Results:
We recruited 90 participants in the acute MDD group, 60 in the MDD in remission group, and 70 healthy controls. After adjusting for demographics, a significant difference in baseline XPO6 mRNA levels was found among the three groups (F = 4.34, p = 0.014). In the post hoc analysis, a stepwise pattern in XPO6 mRNA levels was observed (acute MDD group > MDD in remission group > healthy controls). After antidepressant treatment in the acute MDD group, XPO6 mRNA levels significantly decreased (2.23 ± 2.39 vs. 1.82 ± 1.96, p = 0.016).
Conclusion:
XPO6 mRNA levels could be a potential biomarker for MDD, which is also associated with depression disease state and treatment response to antidepressants. Larger sample sizes are needed to confirm these results in the future.
Insights
Exportin-6 (XPO6) mRNA levels are elevated in major depressive disorder (MDD) and decrease with treatment. This suggests XPO6 may be a biomarker for MDD, reflecting disease state and antidepressant response.
Area of Science:
- Neuroscience
- Molecular Biology
- Psychiatry
Background:
- Exportin-6 (XPO6) is crucial for nuclear export of actin-related proteins, impacting cytoskeletal integrity and synaptic function.
- Dysregulation of these processes is implicated in mood disorders, but XPO6's specific role in major depressive disorder (MDD) is unclear.
Purpose of the Study:
- To investigate XPO6 mRNA levels in patients with MDD compared to healthy controls.
- To examine changes in XPO6 mRNA levels following antidepressant treatment in MDD patients.
Main Methods:
- Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to measure XPO6 mRNA in peripheral blood.
- Participants included individuals with acute MDD, MDD in remission, and healthy controls.
- Depression severity was assessed using the 17-item Hamilton Depression Rating Scale.
Main Results:
- Significant differences in baseline XPO6 mRNA levels were observed across the three groups (P=0.014).
- A stepwise pattern was noted: acute MDD > MDD in remission > healthy controls.
- XPO6 mRNA levels significantly decreased after four weeks of antidepressant treatment in the acute MDD group (P=0.016).
Conclusions:
- XPO6 mRNA levels may serve as a potential biomarker for MDD.
- XPO6 levels correlate with the disease state of depression and response to antidepressant therapy.
- Larger studies are recommended for confirmation.
Related Concept Videos
01:27Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
01:27Depressive Disorders: MDD and Dysthymia
01:24Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
01:23Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
02:41Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
02:31Nuclear Export of mRNA